GERMANTOWN, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology ...

Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose ...

The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons ...

The Eversense 365 is the first one-year continuous ... so that patients can focus on managing their diabetes and not their CGM. E3 in persons with diabetes age 18 and older. The systems are ...

Senseonics Holdings, Inc.’s SENS share price has dipped by 5.52%, which has investors questioning if this is right time to ...

Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365. These are once-yearly implantable CGM systems to measure glucose levels in people with diabetes. In Q4 2024 ...